{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:29:56Z","timestamp":1778660996726,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Janssen EMEA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s12325-023-02700-0","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T09:02:12Z","timestamp":1698310932000},"page":"34-64","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Treatment-Resistant Depression in Real-World Clinical Practice: A Systematic Literature Review of Data from 2012 to 2022"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5071-3007","authenticated-orcid":false,"given":"Albino J.","family":"Oliveira-Maia","sequence":"first","affiliation":[]},{"given":"Ania","family":"Bobrowska","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8023-1535","authenticated-orcid":false,"given":"Eric","family":"Constant","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-638X","authenticated-orcid":false,"given":"Tetsuro","family":"Ito","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0362-8373","authenticated-orcid":false,"given":"Yerkebulan","family":"Kambarov","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8290-600X","authenticated-orcid":false,"given":"Hannah","family":"Luedke","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9708-4356","authenticated-orcid":false,"given":"Siobh\u00e1n","family":"Mulhern-Haughey","sequence":"additional","affiliation":[]},{"given":"Christian","family":"von Holt","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"2700_CR1","doi-asserted-by":"publisher","first-page":"204209862093789","DOI":"10.1177\/2042098620937899","volume":"11","author":"MS Salahudeen","year":"2020","unstructured":"Salahudeen MS, Wright CM, Peterson GM. Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. Ther Adv Drug Saf. 2020;11:2042098620937899.","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"2700_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0896-6273(00)00112-4","volume":"28","author":"M Fava","year":"2000","unstructured":"Fava M, Kendler KS. Major Depressive Disorder. Neuron. 2000;28(2):335\u201341.","journal-title":"Neuron"},{"issue":"1","key":"2700_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12888-019-2222-4","volume":"19","author":"DH Jaffe","year":"2019","unstructured":"Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 2019;19(1):247.","journal-title":"BMC Psychiatry"},{"key":"2700_CR4","unstructured":"National Institute for Health and Care Excellence. Depression in adults: treatment and management (NG222) 2022. https:\/\/www.nice.org.uk\/guidance\/ng222\/resources\/depression-in-adults-treatment-and-management-pdf-66143832307909. Accessed 7 Dec 2022."},{"issue":"11","key":"2700_CR5","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905\u201317.","journal-title":"Am J Psychiatry"},{"issue":"1\u20132","key":"2700_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0924-977X(98)00004-2","volume":"9","author":"D Souery","year":"1999","unstructured":"Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9(1\u20132):83\u201391.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2700_CR7","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of depression. EMA\/CHMP\/185423\/2010 Rev 2 2013. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-depression_en.pdf. Accessed 18 Aug 2022."},{"key":"2700_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/PPA.S29716","volume":"6","author":"KS Al-Harbi","year":"2012","unstructured":"Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369\u201388.","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"2700_CR9","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.8133tx4c","volume":"72","author":"ME Thase","year":"2011","unstructured":"Thase ME. Treatment-resistant depression: prevalence, risk factors, and treatment strategies. J Clin Psychiatry. 2011;72(5): e18.","journal-title":"J Clin Psychiatry"},{"key":"2700_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jad.2020.11.124","volume":"283","author":"K Heerlein","year":"2021","unstructured":"Heerlein K, Young AH, Otte C, Frodl T, Degraeve G, Hagedoorn W, Oliveira-Maia AJ, Perez Sola V, Rathod S, Rosso G. Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics. J Affect Disord. 2021;283:115\u201322.","journal-title":"J Affect Disord"},{"issue":"8","key":"2700_CR11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1176\/appi.ps.201300059","volume":"65","author":"DA Mrazek","year":"2014","unstructured":"Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996\u20132013. Psychiatr Serv (Washington, DC). 2014;65(8):977\u201387.","journal-title":"Psychiatr Serv (Washington, DC)"},{"key":"2700_CR12","doi-asserted-by":"crossref","unstructured":"Halaris A, Sohl E, Whitham EA. Treatment-resistant depression revisited: a glimmer of hope. J Pers Med. 2021;11(2).","DOI":"10.3390\/jpm11020155"},{"issue":"11","key":"2700_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.4088\/JCP.v63n1102","volume":"63","author":"WH Crown","year":"2002","unstructured":"Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63(11):963\u201371.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"2700_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.31887\/DCNS.2008.10.4\/jmendlewicz","volume":"10","author":"J Mendlewicz","year":"2008","unstructured":"Mendlewicz J. Towards achieving remission in the treatment of depression. Dialogues Clin Neurosci. 2008;10(4):371\u20135.","journal-title":"Dialogues Clin Neurosci"},{"issue":"11","key":"2700_CR15","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1176\/ps.2009.60.11.1439","volume":"60","author":"BN Gaynes","year":"2009","unstructured":"Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush JA. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Services. 2009;60(11):1439\u201345.","journal-title":"Psychiatr Services"},{"key":"2700_CR16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jad.2021.03.073","volume":"290","author":"K Heerlein","year":"2021","unstructured":"Heerlein K, Perugi G, Otte C, Frodl T, Degraeve G, Hagedoorn W, et al. Real-world evidence from a European cohort study of patients with treatment resistant depression: treatment patterns and clinical outcomes. J Affect Disord. 2021;290:334\u201344.","journal-title":"J Affect Disord"},{"issue":"2","key":"2700_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.31887\/DCNS.2015.17.2\/dionescu","volume":"17","author":"DF Ionescu","year":"2015","unstructured":"Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci. 2015;17(2):111\u201326.","journal-title":"Dialogues Clin Neurosci"},{"key":"2700_CR18","unstructured":"European Medicines Agency. Esketamine Nasal Spray Summary of Product Characteristics 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spravato. Accessed 18 Aug 2022."},{"key":"2700_CR19","unstructured":"Food and Drug Administration. Spravato Prescribing Information 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211243lbl.pdf. Accessed 18 Aug 2022."},{"key":"2700_CR20","unstructured":"Food and Drug Administration. Symbyax Prescribing Information 2009. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021520s022lbl.pdf. Accessed 7 Dec 2022."},{"issue":"3","key":"2700_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.brs.2012.06.006","volume":"6","author":"CP Furtado","year":"2013","unstructured":"Furtado CP, Hoy KE, Maller JJ, Savage G, Daskalakis ZJ, Fitzgerald PB. An investigation of medial temporal lobe changes and cognition following antidepressant response: a prospective rTMS study. Brain Stimul. 2013;6(3):346\u201354.","journal-title":"Brain Stimul"},{"key":"2700_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.eurpsy.2017.03.012","volume":"44","author":"K Feffer","year":"2017","unstructured":"Feffer K, Lapidus KAB, Braw Y, Bloch Y, Kron S, Netzer R, et al. Factors associated with response after deep transcranial magnetic stimulation in a real-world clinical setting: results from the first 40 cases of treatment-resistant depression. Eur Psychiatry. 2017;44:61\u20137.","journal-title":"Eur Psychiatry"},{"issue":"4","key":"2700_CR23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.brs.2017.03.013","volume":"10","author":"AJ Oliveira-Maia","year":"2017","unstructured":"Oliveira-Maia AJ, Press D, Pascual-Leone A. Modulation of motor cortex excitability predicts antidepressant response to prefrontal cortex repetitive transcranial magnetic stimulation. Brain Stimul. 2017;10(4):787\u201394.","journal-title":"Brain Stimul"},{"issue":"1","key":"2700_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.euroneuro.2017.11.011","volume":"28","author":"K Feffer","year":"2018","unstructured":"Feffer K, Fettes P, Giacobbe P, Daskalakis ZJ, Blumberger DM, Downar J. 1 Hz rTMS of the right orbitofrontal cortex for major depression: safety, tolerability and clinical outcomes. Eur Neuropsychopharmacol. 2018;28(1):109\u201317.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"2700_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4103\/psychiatry.IndianJPsychiatry_182_16","volume":"60","author":"R Verma","year":"2018","unstructured":"Verma R, Kumar N, Kumar S. Effectiveness of adjunctive repetitive transcranial magnetic stimulation in management of treatment-resistant depression: a retrospective analysis. Indian J Psychiatry. 2018;60(3):329\u201333.","journal-title":"Indian J Psychiatry"},{"issue":"16","key":"2700_CR26","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/WNR.0000000000001523","volume":"31","author":"AM Fukuda","year":"2020","unstructured":"Fukuda AM, Hindley LE, Kang JWD, Tirrell E, Tyrka AR, Ayala A, et al. Peripheral vascular endothelial growth factor changes after transcranial magnetic stimulation in treatment-resistant depression. NeuroReport. 2020;31(16):1121\u20137.","journal-title":"NeuroReport"},{"key":"2700_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jpsychires.2022.03.030","volume":"150","author":"C Toth","year":"2022","unstructured":"Toth C, King Johnson ML, Heinzerling A, Trapp N. Response to TMS treatment for depression associated with higher levels of psychological well-being. J Psychiatr Res. 2022;150:142\u20136.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"2700_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.9758\/cpn.2013.11.1.34","volume":"11","author":"Y Tokutsu","year":"2013","unstructured":"Tokutsu Y, Umene-Nakano W, Shinkai T, Yoshimura R, Okamoto T, Katsuki A, et al. Follow-up study on electroconvulsive therapy in treatment-resistant depressed patients after remission: a chart review. Clin Psychopharmacol Neurosci. 2013;11(1):34\u20138.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"12","key":"2700_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci10120971","volume":"10","author":"J Slupski","year":"2020","unstructured":"Slupski J, Cubala WJ, Gorska N, Slupska A, Galuszko-Wegielnik M. Copper concentrations in ketamine therapy for treatment-resistant depression. Brain Sci. 2020;10(12):1\u20139.","journal-title":"Brain Sci"},{"key":"2700_CR30","unstructured":"Nguyen J, Boerth J, Lacro J. Influence of cannabis on effectiveness of esketamine and ketamine for treatment resistant depression. In: College of Psychiatric and Neurologic Pharmacists (CPNP) Annual Meeting. 2022."},{"issue":"4","key":"2700_CR31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/13651501.2022.2030757","volume":"26","author":"L Samalin","year":"2022","unstructured":"Samalin L, Rotharmel M, Mekaoui L, Gaudre-Wattinne E, Codet MA, Bouju S, et al. Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme. Int J Psychiatry Clin Pract. 2022;26(4):352\u201362.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"1","key":"2700_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/PRA.0000000000000277","volume":"24","author":"S Chugh","year":"2018","unstructured":"Chugh S, Chhabria A, Jung S, Kruger THC, Wollmer MA. Botulinum toxin as a treatment for depression in a real-world setting. J Psychiatr Pract. 2018;24(1):15\u201320.","journal-title":"J Psychiatr Pract"},{"issue":"2","key":"2700_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3109\/15622975.2015.1073856","volume":"17","author":"MF Ghabrash","year":"2016","unstructured":"Ghabrash MF, Comai S, Tabaka J, Saint-Laurent M, Booij L, Gobbi G. Valproate augmentation in a subgroup of patients with treatment-resistant unipolar depression. World J Biol Psychiatry. 2016;17(2):165\u201370.","journal-title":"World J Biol Psychiatry"},{"key":"2700_CR34","doi-asserted-by":"publisher","first-page":"110425","DOI":"10.1016\/j.pnpbp.2021.110425","volume":"112","author":"A Tundo","year":"2022","unstructured":"Tundo A, Betro S, Iommi M, de Filippis R. Efficacy and safety of 24-week pramipexole augmentation in patients with treatment resistant depression. A retrospective cohort study. Prog Neuropsychopharmacol Biol Psychiatry. 2022;112:110425.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"2700_CR35","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/JCP.0000000000000945","volume":"38","author":"R Ferreira-Garcia","year":"2018","unstructured":"Ferreira-Garcia R, Da Rocha Freire RC, Appolinario JC, Levitan MN, Halkjaer-Lassen RD, Bueno JR, et al. Tranylcypromine plus amitriptyline for electroconvulsive therapy-resistant depression. J Clin Psychopharmacol. 2018;38(5):502\u20134.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"2700_CR36","first-page":"625","volume":"73","author":"JL Phillips","year":"2012","unstructured":"Phillips JL, Batten LA, Aldosary F, Tremblay P, Blier P. Brain-volume increase with sustained remission in patients with treatment-resistant unipolar depression. J Clin Psychopharmacol. 2012;73(5):625\u201331.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"2700_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/YIC.0000000000000196","volume":"33","author":"G Gobbi","year":"2018","unstructured":"Gobbi G, Ghabrash MF, Nunez N, Tabaka J, Di Sante J, Saint-Laurent M, et al. Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression. Int Clin Psychopharmacol. 2018;33(1):34\u201343.","journal-title":"Int Clin Psychopharmacol"},{"key":"2700_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jad.2020.11.124","volume":"283","author":"K Heerlein","year":"2021","unstructured":"Heerlein K, Young AH, Otte C, Frodl T, Degraeve G, Hagedoorn W, et al. Real-world evidence from a European cohort study of patients with treatment resistant depression: baseline patient characteristics. J Affect Disord. 2021;283:115\u201322.","journal-title":"J Affect Disord"},{"issue":"4","key":"2700_CR39","first-page":"FC4","volume":"15","author":"Kavita","year":"2021","unstructured":"Kavita, Sahu MK, Dhone PG, Tiwari RK, Hishikar R. A prospective observational study on the effects of antidepressant treatment on hypothalamic-pituitary-adrenal axis regulation in treatment-resistant depression. J Clin Diagn Res. 2021;15(4):FC4\u20137.","journal-title":"J Clin Diagn Res"},{"key":"2700_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.769693","volume":"12","author":"G Perugi","year":"2021","unstructured":"Perugi G, Calo P, De Filippis S, Rosso G, Vita A, Adami M, et al. Clinical features and outcomes of 124 Italian patients with treatment resistant depression: a real-world, prospective study. Front Psychiatry. 2021;12: 769693.","journal-title":"Front Psychiatry"},{"issue":"2","key":"2700_CR41","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jad.2013.04.028","volume":"150","author":"M Zimmerman","year":"2013","unstructured":"Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton Depression Rating Scale. J Affect Disord. 2013;150(2):384\u20138.","journal-title":"J Affect Disord"},{"issue":"2","key":"2700_CR42","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0165-0327(99)00162-7","volume":"60","author":"MJ M\u00fcller","year":"2000","unstructured":"M\u00fcller MJ, Szegedi A, Wetzel H, Benkert O. Moderate and severe depression. Gradations for the Montgomery-Asberg Depression Rating Scale. J Affect Disord. 2000;60(2):137\u201340.","journal-title":"J Affect Disord"},{"key":"2700_CR43","doi-asserted-by":"crossref","unstructured":"Beck AT, Steer RA, Brown GK. BDI-II, Beck Depression Inventory: manual: Psychological Corp; 1996.","DOI":"10.1037\/t00742-000"},{"issue":"9","key":"2700_CR44","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"2700_CR45","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jpsychires.2004.03.007","volume":"38","author":"M Zimmerman","year":"2004","unstructured":"Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg Depression Rating Scale corresponding to the definition of remission on the Hamilton Rating Scale for depression. J Psychiatr Res. 2004;38(6):577\u201382.","journal-title":"J Psychiatr Res"},{"issue":"15","key":"2700_CR46","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jpsychires.2010.03.006","volume":"44","author":"M Riedel","year":"2010","unstructured":"Riedel M, M\u00f6ller HJ, Obermeier M, Schennach-Wolff R, Bauer M, Adli M, et al. Response and remission criteria in major depression\u2013a validation of current practice. J Psychiatr Res. 2010;44(15):1063\u20138.","journal-title":"J Psychiatr Res"},{"issue":"2","key":"2700_CR47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamapsychiatry.2022.3860","volume":"80","author":"J Lundberg","year":"2022","unstructured":"Lundberg J, Cars T, L\u00f6\u00f6v S-\u00c5, S\u00f6derling J, Sundstr\u00f6m J, Tiihonen J, et al. Association of treatment-resistant depression with patient outcomes and health care resource utilization in a population-wide study. JAMA Psychiat. 2022;80(2):167\u201375.","journal-title":"JAMA Psychiat"},{"key":"2700_CR48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-94-007-7596-1_3","volume-title":"Self-reported population health: an international perspective based on EQ-5D","author":"B Janssen","year":"2014","unstructured":"Janssen B, Szende A. Population norms for the EQ-5D. In: Szende A, Janssen B, Cabases J, editors. Self-reported population health: an international perspective based on EQ-5D. Dordrecht: Springer; 2014. p. 19\u201330."},{"key":"2700_CR49","unstructured":"Lefebvre C GJ, Briscoe S, Featherstone R, Littlewood A, Marshall C, Metzendorf M-I, Noel-Storr A, Paynter R, Rader T, Thomas J, Wieland LS. Chapter 4: Searching for and selecting studies. 2022. In: Cochrane handbook for systematic reviews of interventions [Internet]. Cochrane. Available from: www.training.cochrane.org\/handbook. Accessed 2 June 2023."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02700-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02700-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02700-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T22:06:09Z","timestamp":1705615569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02700-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2700"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02700-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"25 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Albino J. Oliveira-Maia: Received grants from Schuhfried GmBH, Janssen and Compass Pathways, Ltd; received payment, honoraria, travel support or advisory board fees from MSD, Janssen, Angelini, Neurolite AG, and the European Monitoring Centre for Drugs and Drug Addiction; investigator-driven research funded by Funda\u00e7\u00e3o para Ci\u00eancia e Tecnologia (PTDC\/SAU-NUT\/3507\/2021; PTDC\/MED-NEU\/1552\/2021; PTDC\/MED-NEU\/31331\/2017), Funda\u00e7\u00e3o para Ci\u00eancia e Tecnologia and FEDER (PTDC\/MED-NEU\/30845\/2017_LISBOA-01\u20130145-FEDER-030845; FCT-PTDC\/MEC-PSQ\/30302\/2017-IC&DTLISBOA-01-0145-FEDER), the European Commission Horizon 2020 program (H2020-SC1-2017-CNECT-2-777167-\u0392\u039fUNCE; H2020-SC1-DTH-2019-875358-FAITH), the European Research Council (grant ERC-2020-STG-Grant agreement 950357) and the European Joint Programme in Rare Diseases (Joint Translational Call 2019) through Funda\u00e7\u00e3o para Ci\u00eancia e Tecnologia (EJPRD\/0001\/2020); Vice-President of the Portuguese Society for Psychiatry and Mental Health; Head of the Psychiatry Working Group for the National Board of Medical Examination (GPNA) at the Portuguese Medical Association and Portuguese Ministry of Health. Eric Constant: Received honoraria, advisory board fees and travel support from AstraZeneca, BMS, Lilly, Wyeth, Servier, Janssen Cilag, Pfizer, Lundbeck, Viatris and Teva. Tetsuro Ito, Yerkebulan Kambarov, Siobh\u00e1n Mulhern-Haughey, Christian von Holt: Employees of Janssen; hold Johnson & Johnson company stocks\/stock options. Ania Bobrowska, Hannah Luedke: Employees of Costello Medical, UK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}